This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Beta-1 adrenergic receptor.
Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling. .
Human | |
---|---|
Gene Name: | ADRB1 |
Uniprot: | P08588 |
Entrez: | 153 |
Belongs to: |
---|
G-protein coupled receptor 1 family |
ADRB1; ADRB1R; ADRB1RRHR; adrenergic, beta-1-, receptor; B1AR; beta-1 Adrenergic R; beta-1 adrenergic receptor; beta1 AdrenergicR; beta-1 AdrenergicR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; BETA1AR
Mass (kDA):
51.323 kDA
Human | |
---|---|
Location: | 10q25.3 |
Sequence: | 10; NC_000010.11 (114043866..114046904) |
Cell membrane; Multi-pass membrane protein. Early endosome. Colocalizes with RAPGEF2 at the plasma membrane (By similarity). Localized at the plasma membrane. Found in the Golgi upon GOPC overexpression.
One of the most misunderstood genes, the ADRB1 is vital for understanding various conditions. The regulation of growth of various body tissues including the brain and retina is a function of the ADRB1 gene. The ADRB1 gene isn't the only one involved in this process. Other genes, like ADRB3, can also be involved in the development of diseases such as cancer and heart disease. The Boster gene infographics give basic information about each of the genes. You can also search for them in the "genetically” section.
The ADRB1 protein is highly expressed in many types cancers. This protein is also known a b - AR. It is closely linked to the survival rate of patients with cancer. The ADRB1 gene has been found in both mouse and human cells. This marker is used most often in cancer research. It has many uses, including cancer diagnosis and prognosis.
Researchers have discovered a novel mutation that causes a C–to–T transition in ADRB1 genes. The mutation, A187V, affects the ADRB1 protein in the fourth transmembrane domain. This mutation has been shown in mice to alter the sleep-wake cycle. It also segregates with a phenotype within a mouse family. In addition, the ADRB1 gene is mutated, and the mutant form is less stable than wild-type, indicating that the ADRB1 mutation has functional implications in the brain.
HCC diagnosis is not limited to the ADRB1 marker. Researchers also found evidence of a protective role for ADRB1 in the development the disease. Researchers have shown ADRB1 is downregulated in HCC tumor tissues and that its expression is associated to patient survival. However, the exact role of HCC b–ARs has not been determined. It is therefore necessary to conduct more research in order to identify patients with HCC and develop a biomarker that can be used to diagnose them.
ADRB1 is a gene whose methylation status is inversely correlated with the expression of the gene. Additionally, ADRA1A expression in HCC was found to be lower than normal and was associated with hypermethylation of the ADRB1 promoter. Although this correlation is not yet clear, it demonstrates that ADRA1A is an important biomarker of HCC. This marker will be used to screen HCC patients with high levels ADRB1 gene.
The HCC risk adjustment model assigns a risk adjustment factor to every Medicare patient. To calculate reimbursements physicians must document the diagnosis and treatment of patients using HCC. The RAF is linked to the HCC. Healthcare organizations can increase their EMR, data, and education to better document HCC patients by identifying them. Accurate documentation also leads to better HCC risk adjustment coding, and appropriate compensation.
It has been challenging to molecularly analyze the ADRB1 protein, and its coreceptors. Lee et.al. Lee et.al. have shown that ADRB1 has a different relationship to nanobodies than Gs. The ARRB1 finger loop had a narrower intracellular surface than Gs and was coupled through a distinct mechanism.
Researchers can also access the gene infographics to find additional information. These infographics provide basic information about ADRB1 genes. These information graphic resources cover all genes in humans as well as mice. The gene search tool allows users to search for a particular gene. Boster offers more information. Below is a table highlighting the benefits and drawbacks of ADRB1-based biomarker testing.
MiRNA-423-5p, a novel miRNA that has a high molecular mass, appears to have similar diagnostic properties to existing biomarkers. However, the exact diagnostic value of miRNA-423-5p is unknown. To avoid significant bias, the miRNA-423-5p marker was chosen from the total miRNAs. The miR-423-5p result also reached the diagnostic level.
The main goals of therapy to treat HF-AF are to prevent stroke, control ventricular rates, and improve QOL. Patients with HFAF who are unable to use the ADRB1 marker have a few, but not all, options. Catheter ablation, however, is still the best choice. It also reduces the patient's burden. Cardiopulmonary exercise testing is an option for those with more severe cases.
While the ADRB1 Polymorphism has been shown to be associated with mortality and HF outcome in the past, the association between the GRK5 receptor and the b1–adrenergic receptor is not always consistent. It is a good indicator of a genetic risk factor in HF. Researchers are also trying to determine if there is a relationship between polymorphisms at the b1-adrenergic receptor gene and HF outcome.
PMID: 2825170 by Frielle T., et al. Cloning of the cDNA for the human beta 1-adrenergic receptor.
PMID: 10477438 by Moore J.D., et al. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C.